Abstract:Alzheimer's disease (AD) is affecting more and more people worldwide without the effective treatment, while the existed pathological mechanism has been confirmed barely useful in the treatment. Amyloid-β peptide (Aβ), a main component of senile plaque, is regarded as the most promising target in AD treatment. Aβ clearance from AD brain seems to be a reliably therapeutic strategy, as the two exited drugs, GV-971 and aducanumab, are both developed based on it. However, doubt still exists. To exhaustive expound on the pathological mechanism of Aβ, rigorous analyses on the concentrations and aggregation forms are essential. Thus, it is attracting broad attention these years. However, most of the sensors have not been used in pathological studies, as the lack of the bridge between analytical chemist and pathologists. In this review, we made a brief introduce on Aβ-related pathological mechanism included in β-amyloid hypothesis to elucidate the detection conditions of sensor methods. Furthermore, a summary of the sensor methods was made, which were based on Aβ concentrations and form detections that have been developed in the past 10 years. As the greatest number of the sensors were built on fluorescent spectroscopy, electrochemistry, and Roman spectroscopy, detailed elucidation on them was made. Notably, the aggregation process is another important factor in revealing the progress of AD and developing the treatment methods, so the sensors on monitoring Aβ aggregation processes were also summarized.

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

Recent Developments in the Chemical Biology of Amyloid-Β Oligomer Targeting

Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects

Strategies for Measuring Concentrations and Forms of Amyloid-Β Peptides

Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Advances in Detection Methods of Β-Amyloid Protein

Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators.

Fabrication of an Antibody-Aptamer Sandwich Assay for Electrochemical Evaluation of Levels of Β-Amyloid Oligomers

Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects

Advances in Detection Methods of beta-Amyloid Protein

Selective Amyloid Β Oligomer Assay Based on Abasic Site-Containing Molecular Beacon and Enzyme-Free Amplification.

Aβ-binding molecules: Possible application as imaging probes and as anti-aggregation agents

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Fluorescence Detection and Dissociation of Amyloid‐β Species for the Treatment of Alzheimer's Disease

Electrochemical Sensors Based On Bioreceptors For Detecting Different Conformations Of Amyloid-Beta Peptides

Progress in soluble Aβ oligomers in Alzheimer's disease and drugs targeting Aβ oligomers

An Updated Review of Amyloid Beta Oligomer Toxicity Inhibition and Detection for Alzheimer's Disease Diagnosis

In Situ Monitoring the Aggregation Dynamics of Amyloid-β Protein Aβ42 in Physiological Media Via a Raman-Based Frequency Shift Method.

Cerebrospinal Fluid and Blood Biomarkers in the Diagnostic Assays of Alzheimer’s Disease

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression